TY - JOUR T1 - Azithromycin for Treatment of Hospitalised COVID-19 Patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00610-2021 SP - 00610-2021 AU - Iwein Gyselinck AU - Laurens Liesenborghs AU - Ann Belmans AU - Matthias M. Engelen AU - Albrecht Betrains AU - Quentin Van Thillo AU - Pham Anh Hong Nguyen AU - Pieter Goeminne AU - Ann-Catherine Soenen AU - Nikolaas De Maeyer AU - Charles Pilette AU - Emmanuelle Papleux AU - Eef Vanderhelst AU - Aurélie Derweduwen AU - Patrick Alexander AU - Bernard Bouckaert AU - Jean-Benoît Martinot AU - Lynn Decoster AU - Kurt Vandeurzen AU - Rob Schildermans AU - Peter Verhamme AU - Wim Janssens AU - Robin Vos AU - for the DAWn-AZITHRO investigators Y1 - 2022/01/01 UR - http://openres.ersjournals.com/content/early/2022/01/06/23120541.00610-2021.abstract N2 - Background and objectives Azithromycin was rapidly adopted as a repurposed drug to treat COVID-19 early in the pandemic. We aimed to evaluate its efficacy in patients hospitalised for COVID-19.Methods In a series of randomised, open-label, phase 2 proof-of-concept, multicenter clinical trials (Direct Antivirals Working against the novel Coronavirus [DAWn]), several treatments were compared with standard of care. In 15 Belgian hospitals, patients hospitalised with moderate to severe COVID-19 patients were allocated 2:1 to receive standard of care plus azithromycin or standard of care alone. The primary outcome was time to live discharge or sustained clinical improvement, defined as a two-point improvement on the WHO ordinal scale sustained for at least 3 days.Results Patients were included between April 22 and December 17, 2020. When 15-day follow-up data were available for 160 patients (56% of preset cohort), an interim analysis was performed at request of the independent Data Safety and Monitoring Board. Subsequently, DAWn-AZITHRO was stopped for futility. In total, 121 patients were allocated to the treatment arm and 64 patients to the standard of care arm. We found no effect of azithromycin on the primary outcome with Hazard ratio of 1.044 (95% confidence interval, 0.772–1.413; p=0.7798). None of the predefined subgroups showed significant interaction as covariates in the Fine-Gray regression analysis. No benefit of azithromycin was found on any of the short- and longer-term secondary outcomes.Conclusion Time to clinical improvement is not influenced by azithromycin in patients hospitalised with moderate to severe COVID-19. ER -